, Volume 34, Issue 10, pp 2492-2493
Date: 04 May 2010

To Resect or not the Primary Tumor in Metastatic Colorectal Cancer: Letter to the Editor

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Colorectal cancer (CRC) is one of the most common tumors in the US, Europe, and worldwide but with a relatively good prognosis. In the adjuvant setting, high long-term survival rates have been reported, and even in the metastatic setting, with the use of systemic chemotherapy the median survival time has been improved to roughly 20 months. The addition of biologic agents such as cetuximab or panitumab has raised expectation for further survival improvement. With these developments, an old problem in surgical oncology has now been updated. Is the decision to resect the primary tumor, when it is locally completely resectable, correct, or will resection harm patients with a stage IV disease?

To highlight this critical question in day-to-day clinical practice, Stillwell et al. [1] performed a meta-analysis and reported the results in the April 2010 issue of this journal. The authors concluded that palliative primary tumor resection in metastatic CRC (mCRC) prolongs survival and benefits pat ...